Seasonal Influenza Vaccination for Children in Thailand: A Cost-Effectiveness Analysis
Ben Cooper and colleagues use an age-structured model to estimate optimal cost-effectiveness of flu vaccination among Thai children aged 2 to 17.
Vyšlo v časopise:
Seasonal Influenza Vaccination for Children in Thailand: A Cost-Effectiveness Analysis. PLoS Med 12(5): e32767. doi:10.1371/journal.pmed.1001829
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pmed.1001829
Souhrn
Ben Cooper and colleagues use an age-structured model to estimate optimal cost-effectiveness of flu vaccination among Thai children aged 2 to 17.
Zdroje
1. Jit M, Newall AT, Beutels P. Key issues for estimating the impact and cost-effectiveness of seasonal influenza vaccination strategies. Hum Vaccin Immunother 2013;9:834–840. doi: 10.4161/hv.23637 23357859
2. Baguelin M, Flasche S, Camacho A, Demiris N, Miller E, Edmunds WJ. Assessing optimal target populations for influenza vaccination programmes: an evidence synthesis and modelling study. PLoS Med 2013;10:e1001527. doi: 10.1371/journal.pmed.1001527 24115913
3. Longini IM Jr. A theoretic framework to consider the effect of immunizing schoolchildren against influenza: implications for research. Pediatrics 2012;129 Suppl 2:S63–S67. doi: 10.1542/peds.2011-0737D 22383483
4. Ndeffo Mbah ML, Medlock J, Meyers LA, Galvani AP, Townsend JP. Optimal targeting of seasonal influenza vaccination toward younger ages is robust to parameter uncertainty. Vaccine 2013;31:3079–3089. doi: 10.1016/j.vaccine.2013.04.052 23684837
5. Basta NE, Chao DL, Halloran ME, Matrajt L, Longini IM Jr. Strategies for pandemic and seasonal influenza vaccination of schoolchildren in the United States. Am J Epidemiol 2009;170:679–686. doi: 10.1093/aje/kwp237 19679750
6. Vynnycky E, Pitman R, Siddiqui R, Gay N, Edmunds WJ. Estimating the impact of childhood influenza vaccination programmes in England and Wales. Vaccine 2008;26:5321–5330. doi: 10.1016/j.vaccine.2008.06.101 18647634
7. Pitman RJ, White LJ, Sculpher M. Estimating the clinical impact of introducing paediatric influenza vaccination in England and Wales. Vaccine. 2012;30:1208–1224. doi: 10.1016/j.vaccine.2011.11.106 22178725
8. Reichert TA, Sugaya N, Fedson DS, Glezen WP, Simonsen L, Tashiro M. The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med 2001;344:889–896. 11259722
9. Dawood FS, Prapasiri P, Areerat P, Ruayajin A, Chittaganpitch M, Muangchana C, et al. Effectiveness of the 2010 and 2011 Southern Hemisphere trivalent inactivated influenza vaccines against hospitalization with influenza-associated acute respiratory infection among Thai adults aged ≥ 50 years. Influenza Other Respir Viruses 2014;8:463–468. doi: 10.1111/irv.12233 24490684
10. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:36–44. doi: 10.1016/S1473-3099(11)70295-X 22032844
11. Briggs AH. A Bayesian approach to stochastic cost-effectiveness analysis. Health Econ 1999;8:257–261. 10348420
12. Barton GR, Briggs AH, Fenwick EA. Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). Value Health 2008;11:886–897. doi: 10.1111/j.1524-4733.2008.00358.x 18489513
13. Sadatsafavi M, Bansback N, Zafari Z, Najafzadeh M, Marra C. Need for speed: an efficient algorithm for calculation of single-parameter expected value of partial perfect information. Value Health 2013;16:438–448. doi: 10.1016/j.jval.2012.10.018 23538197
14. Cauchemez S, Bhattarai A, Marchbanks TL, Fagan RP, Ostroff S, Ferguson NM, et al. Role of social networks in shaping disease transmission during a community outbreak of 2009 H1N1 pandemic influenza. Proc Natl Acad Sci U S A 2011;108:2825–2830. doi: 10.1073/pnas.1008895108 21282645
15. Carrat F, Vergu E, Ferguson NM, Lemaitre M, Cauchemez S, Leach S, et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol 2008;167:775–785. doi: 10.1093/aje/kwm375 18230677
16. Chittaganpitch M, Supawat K, Olsen SJ, Waicharoen S, Patthamadilok S, Yingyong D, et al. Influenza viruses in Thailand: 7 years of sentinel surveillance data, 2004–2010. Influenza Other Respir Viruses 2012;6:276–283. doi: 10.1111/j.1750-2659.2011.00302.x 22074057
17. Breteler JK, Tam JS, Jit M, Ket JC, De Boer MR. Efficacy and effectiveness of seasonal and pandemic A (H1N1) 2009 influenza vaccines in low and middle income countries: a systematic review and meta-analysis. Vaccine 2013;31:5168–5177. doi: 10.1016/j.vaccine.2013.08.056 24012574
18. Jefferson T, Rivetti A, Di Pietrantonj C, Demicheli V, Ferroni E. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev. 2012; 8:CD004879. doi: 10.1002/14651858.CD004879.pub4 22895945
19. McKenzie J, Ryan R, Di Tanna GL. Cochrane Consumer and Communication Review Group: cluster randomised controlled trials. Available: http://cccrg.cochrane.org/sites/cccrg.cochrane.org/files/uploads/ClusterRCTs.pdf. Accessed 23 April 2015.
20. Saha S, Chadha M, Al Mamun A, Rahman M, Sturm-Ramirez K, Chittaganpitch M, et al. Influenza seasonality and vaccination timing in tropical and subtropical areas of southern and south-eastern Asia. Bull World Health Organ 2014; 92:318–330. doi: 10.2471/BLT.13.124412 24839321
21. Cooper BS, Kotirum S, Kulpeng W, Praditsitthikorn N, Chittaganpitch M, Limmathurotsakul D, et al. Mortality attributable to seasonal influenza A and B infections in Thailand, 2005–2009: a longitudinal study. Am J Epidemiol 2015 Apr 20. doi: 10.1093/aje/kwu360
22. Zhou Y, Lau EH, Ip DK, Nishiura H, Leung GM, Seto WH, et al. Years of life lost in the first wave of the 2009 influenza A(H1N1) pandemic in Hong Kong. Am J Epidemiol 2013;178:1313–1318. doi: 10.1093/aje/kwt120 23978528
23. Lugner AK, van Boven M, de Vries R, Postma MJ, Wallinga J. Cost effectiveness of vaccination against pandemic influenza in European countries: mathematical modelling analysis. BMJ 2012;345:e4445. doi: 10.1136/bmj.e4445 22791791
24. Prosser LA, Bridges CB, Uyeki TM, Rego VH, Ray GT, Meltzer MI, et al. Values for preventing influenza-related morbidity and vaccine adverse events in children. Health Qual Life Outcomes 2005;3:18. 15780143
25. Program for Appropriate Technology in Health, World Health Organization, Health Systems Research Institute, Mahidol University. An assessment of vaccine supply chain and logistics systems in Thailand. Program for Appropriate Technology in Health; 2011. Available: http://www.path.org/publications/files/TS_opt_vac_sup_thai.pdf. Accessed 23 April 2015.
26. Riewpaiboon A. Standard cost lists for health technology assessment. Nonthaburi (Thailand): Health Intervention and Technology Assessment Program; 2011. Available: http://www.hitap.net/costingmenu/. Accessed 23 April 2015.
27. Simmerman JM, Lertiendumrong J, Dowell SF, Uyeki T, Olsen SJ, Chittaganpitch M, et al. The cost of influenza in Thailand. Vaccine 2006;24:4417–4426. 16621187
28. Dieleman J, Romio S, Johansen K, Weibel D, Bonhoeffer J, Sturkenboom M, et al. Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe. BMJ. 2011;343:d3908. doi: 10.1136/bmj.d3908 21750072
29. Centers for Disease Control and Prevention. Vaccines for Children Program (VFC): CDC vaccine price list. Centers for Disease Control and Prevention; 2014. Available: http://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/. Accessed 23 April 2015.
30. Luce BR, Nichol KL, Belshe RB, Frick KD, Li SX, Boscoe A, et al. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24–59 months in the United States. Vaccine. 2008;26:2841–2848. doi: 10.1016/j.vaccine.2008.03.046 18462851
31. Tarride J-E, Burke N, Von Keyserlingk C, O’Reilly D, Xie F, Goeree R. Cost-effectiveness analysis of intranasal live attenuated vaccine (LAIV) versus injectable inactivated influenza vaccine (TIV) for Canadian children and adolescents. Clinicoecon Outcomes Res. 2012;4:287–298. doi: 10.2147/CEOR.S33444 23055756
32. Damm O, Eichner M, Rose MA, Knuf M, Wutzler P, Liese JG, et al. Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany. Eur J Health Econ. 2014 May 25. doi: 10.1007/s10198-014-0586-4
33. Thai Ministry of Commerce Bureau of Trade and Economic Indices. Report for consumer price index of Thailand year 2007: base year 2011. Available: http://www.indexpr.moc.go.th/price_present/TableIndexG_region.asp?nyear=2550&Province_code=5&table_name=cpig_index_country&type_code=g&check_f=i&comm_code=0&Submit=+%B5%A1%C5%A7+. Accessed 23 April 2015.
34. International Monetary Fund. World economic outlook database, October 2012: Thailand—national currency per current international dollar. Available: http://www.imf.org/external/pubs/ft/weo/2012/02/weodata/weorept.aspx?sy=2010&ey=2017&scsm=1&ssd=1&sort=country&ds=.&br=1&pr1.x=21&pr1.y=9&c=578&s=PPPEX&grp=0&a=. Accessed 23 April 2015.
35. Oakley J, O’Hagan A. SHELF: the Sheffield Elicitation Framework (version 2.0). University of Sheffield School of Mathematics and Statistics; 2014. Available: http://tonyohagan.co.uk/shelf. Accessed 23 April 2015.
36. Horby P, Mai le Q, Fox A, Thai PQ, Thi Thu Yen N, Thanh le T, et al. The epidemiology of interpandemic and pandemic influenza in Vietnam, 2007–2010: the Ha Nam household cohort study I. Am J Epidemiol. 2012;175:1062–1074. doi: 10.1093/aje/kws121 22411862
37. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS—a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput. 2000;10:325–337. 10902901
38. Clover RD, Crawford S, Glezen WP, Taber LH, Matson CC, Couch RB. Comparison of heterotypic protection against influenza A/Taiwan/86 (H1N1) by attenuated and inactivated vaccines to A/Chile/83-like viruses. J Infect Dis. 1999;163:300–4. 1988512
39. Loeb M, Russell ML, Moss L, Fonseca K, Fox J, Earn DJ, et al. Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. JAMA. 2010;303:943–950. doi: 10.1001/jama.2010.250 20215608
40. Belshe RB, Mendelman PM, Treanor J, King J, Gruber WC, Piedra P, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med. 1998;338:1405–1412. 9580647
41. Belshe RB, Gruber WC, Mendelman PM, Cho I, Reisinger K, Block SL, et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr. 2000;136:168–75. 10657821
42. Tam JS, Capeding MR, Lum LC, Chotpitayasunondh T, Jiang Z, Huang LM, et al. Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia. Pediatr Infect Dis J. 2007;26:619–28. 17596805
43. Lum LC, Borja-Tabora CF, Breiman RF, Vesikari T, Sablan BP, Chay OM, et al. Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children. Vaccine. 2010;28:1566–1574. doi: 10.1016/j.vaccine.2009.11.054 20003918
44. World Health Organization. Cost effectiveness and strategic planning (WHO-CHOICE): Cost-effectiveness thresholds. Available: http://www.who.int/choice/costs/CER_thresholds/en/. Accessed 23 April 2015.
45. Clemens J, Brenner R, Rao M, Tafari N, Lowe C. Evaluating new vaccines for developing countries. Efficacy or effectiveness? JAMA. 1996;275:390–397. 8569019
46. Kulpeng W, Leelahavarong P, Rattanavipapong W, Sornsrivichai V, Baggett HC, Meeyai A, et al. Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: protection at what price in the Thai context? Vaccine. 2013;31:2839–2847. doi: 10.1016/j.vaccine.2013.03.047 23588084
47. Muangchana C, Riewpaiboon A, Jiamsiri S, Thamapornpilas P, Warinsatian P. Economic analysis for evidence-based policy-making on a national immunization program: a case of rotavirus vaccine in Thailand. Vaccine. 2012; 30:2839–2847. doi: 10.1016/j.vaccine.2012.02.047 22387220
48. Lowen AC, Mubareka S, Steel J, Palese P. Influenza virus transmission is dependent on relative humidity and temperature. PLoS Pathog 2007;3:1470–1476. 17953482
49. Savidan E, Chevat C, Marsh G. Economic evidence of influenza vaccination in children. Health Policy 2008;86:142–152. 18054109
50. Pitman RJ, Nagy LD, Sculpher MJ. Cost-effectiveness of childhood influenza vaccination in England and Wales: Results from a dynamic transmission model. Vaccine 2013;31:927–942. doi: 10.1016/j.vaccine.2012.12.010 23246550
51. Russell CA, Jones TC, Barr IG, Cox NJ, Garten RJ, Gregory V, et al. The global circulation of seasonal influenza A (H3N2) viruses. Science 2008; 320:340–346. doi: 10.1126/science.1154137 18420927
52. Ferguson NM, Galvani AP, Bush RM. Ecological and immunological determinants of influenza evolution. Nature 2003; 422:428–433. 12660783
53. Wikramaratna PS, Sandeman M, Recker M, Gupta S. The antigenic evolution of influenza: drift or thrift? Philos Trans R Soc Lond B Biol Sci 2013;368:20120200. doi: 10.1098/rstb.2012.0200 23382423
54. Gomes MG, Lipsitch M, Wargo AR, Kurath G, Rebelo C, Medley GF, et al. A missing dimension in measures of vaccination impacts. PLoS Pathog 2014;10:e1003849. doi: 10.1371/journal.ppat.1003849 24603721
55. Van Bellinghen LA, Meier G, Van Vlaenderen I. The potential cost-effectiveness of quadrivalent versus trivalent influenza vaccine in elderly people and clinical risk groups in the UK: a lifetime multi-cohort model. PLoS ONE 2014;9:e98437. doi: 10.1371/journal.pone.0098437 24905235
56. You J, Ming WK, Chan P. Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong. BMC Infect Dis 2014;14:618. doi: 10.1186/s12879-014-0618-9 25420713
57. Cowling BJ, Fang VJ, Nishiura H, Chan KH, Ng S, Ip DK, et al. Increased risk of noninfluenza respiratory virus infections associated with receipt of inactivated influenza vaccine. Clin Infect Dis 2012;54:1778–1783. doi: 10.1093/cid/cis307 22423139
Štítky
Interné lekárstvoČlánok vyšiel v časopise
PLOS Medicine
2015 Číslo 5
- Statinová intolerance
- Očkování proti virové hemoragické horečce Ebola experimentální vakcínou rVSVDG-ZEBOV-GP
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
- Metamizol v liečbe pooperačnej bolesti u detí do 6 rokov veku
- Co dělat při intoleranci statinů?
Najčítanejšie v tomto čísle
- Use of Fixed Dose Combination (FDC) Drugs in India: Central Regulatory Approval and Sales of FDCs Containing Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Metformin, or Psychotropic Drugs
- How Has the Age-Related Process of Overweight or Obesity Development Changed over Time? Co-ordinated Analyses of Individual Participant Data from Five United Kingdom Birth Cohorts
- A Global Biomedical R&D Fund and Mechanism for Innovations of Public Health Importance
- An Unsupported Preference for Intravenous Antibiotics